Two-year Results of Preserflo Microshunt use in Open-angle Glaucoma Surgery

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064190%3A_____%2F25%3A10001475" target="_blank" >RIV/00064190:_____/25:10001475 - isvavai.cz</a>

Result on the web

<a href="https://doi.org/10.31348/2025/9" target="_blank" >https://doi.org/10.31348/2025/9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.31348/2025/9" target="_blank" >10.31348/2025/9</a>

Result language

angličtina

Original language name

Two-year Results of Preserflo Microshunt use in Open-angle Glaucoma Surgery

Original language description

Aim: To evaluate the safety and efficacy outcomes of PRESERFLOTM MicroShunt implantation in patients with primary open-angle glaucoma. Material and Methods: Retrospective data analysis of 19 eyes of 12 patients, comprising 5 females and 7 males. The patients underwent surgery between August 2020 and February 2022. The follow-up period was 24 months after surgery. During the follow-up period, intraocular pressure (IOP), the need to apply topical antiglaucoma medication and its spectrum, visual field status, optic nerve target findings and postoperative complications were recorded. The indication for PRESERFLOTM MicroShunt implantation was primary open angle glaucoma (POAG), poorly controlled with maximum tolerated medical therapy. Results: Average IOP was reduced from 19.05 +-5.58 mmHg preoperatively to 11.47 +-2.48 mmHg at 3 months postoperatively, 12.26 +-2.48 mmHg at 6 months postoperatively, 14.0 +-2.43 mmHg at 12 months postoperatively, 11.78 +-2.37 mmHg at 18 months postoperatively, and 12.73 +-2.51 mmHg at 24 months postoperatively (p &lt; 0.001). No antiglaucoma medication was required in 19 eyes 3 months after surgery, in 19 eyes 6 months after surgery, 19 eyes 12 months after surgery, 16 eyes 18 months after surgery and 15 eyes 24 months after surgery. One eye (5.26%) required monotherapy 18 months after surgery, and 2 eyes (10.52%) 24 months after surgery. Dual combination therapy was required 18 months after surgery in 2 eyes (10.52%) and 24 months after surgery in 2 eyes (10.52%). In the early postoperative period we found a loose conjunctival suture in 3 eyes, which was followed by resuturing in 1 eye. In the late postoperative period we found an obturated implant in 1 eye, which required implant replacement. Conclusion: Our initial results suggest that the PRESERFLOTM MicroShunt glaucoma implant is an effective surgical technique with minimal postoperative complications, resulting in a statistically significant reduction in average IOP and discontinuation or reduction of topical antiglaucoma medication for 2 years after surgery. (C) 2025, Czech Medical Association J.E. Purkyne. All rights reserved.

Czech name

—

Czech description

—

Type

J_SC - Article in a specialist periodical, which is included in the SCOPUS database

CEP classification

—

OECD FORD branch

30207 - Ophthalmology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Česká a Slovenská Oftalmologie

ISSN

1211-9059

e-ISSN

—

Volume of the periodical

81

Issue of the periodical within the volume

4

Country of publishing house

CZ - CZECH REPUBLIC

Number of pages

8

Pages from-to

189-196

UT code for WoS article

—

EID of the result in the Scopus database

2-s2.0-105019666201